With Additional Active Ingredient Patents (Class 514/171)
-
Patent number: 12208103Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.Type: GrantFiled: February 12, 2024Date of Patent: January 28, 2025Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara, Jonathan Ogle, Samuel Akapo, Joel Frank
-
Patent number: 12136474Abstract: A computer-implemented method of providing a dosage and a transgender patient treatment lifecycle comprising receiving, by a computerized device, an input signal of a user indicating an input directed to a patient sex and a patient status, wherein the patient status is automatically determined by the processor and includes at least one of a new patient, a returning patient and a booster patient, determining by the processor at least one of an effective estradiol dosage and an effective testosterone dosage using dosage calculation methods selected based on the patient status, automated male-to-female input parameters or automated female-to-male input parameters, and male-to-female or female-to-male tracking parameters in response to receiving an input indicating that the patient sex is male-to-female or female-to-male, displaying on the display screen, the determined effective dosages, and administering a pellet comprising at least one of the determined effective dosages to the patient.Type: GrantFiled: August 12, 2021Date of Patent: November 5, 2024Assignee: The SottoPelle Group, LLCInventors: Gino Tutera, Stephen Nunn
-
Patent number: 12115159Abstract: The present invention pertains to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, the composition containing G protein coupled receptor 119 (GPR119) ligand as an active ingredient. The pharmaceutical composition according to the present invention exhibits the excellent effects of improving lipid metabolism, reducing fat accumulation in liver tissues, and preventing histological damage caused by inflammation and fibrosis in liver tissues, and can thus be useful in preventing or treating non-alcoholic fatty liver disease.Type: GrantFiled: September 11, 2019Date of Patent: October 15, 2024Assignee: Dong-A St Co., Ltd.Inventors: Mi-Kyung Kim, Bo Ram Lee, Hansu Park, Seung Ho Lee, Yu Na Chae
-
Patent number: 12083131Abstract: Described herein are methods of treating tremor, e.g., essential tremor, depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).Type: GrantFiled: February 10, 2020Date of Patent: September 10, 2024Assignee: Sage Therapeutics, Inc.Inventors: Stephen Jay Kanes, Helen Colquhoun
-
Patent number: 12076329Abstract: The present disclosure provides a conjugate comprising an affinity agent, a branched linker, and two or more photoisomerizable regulators. The present disclosure provides compositions comprising the conjugate, as well as devices comprising the compositions. The present disclosure provides methods for enhancing visual function, the methods comprising administering the conjugate to an individual in need thereof.Type: GrantFiled: May 27, 2021Date of Patent: September 3, 2024Assignees: Cornell Univerisity, MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., The Regents of the University of CaliforniaInventors: Ehud Y. Isacoff, Johannes Broichhagen, Joshua T. Levitz
-
Patent number: 12070442Abstract: Pharmaceutical compositions are described, the compositions comprising an immunosuppressant (such as mycophenolic acid) in combination with a very low concentration of a corticosteroid (such as betamethasone) that are capable of treating, preventing, and/or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.Type: GrantFiled: December 4, 2019Date of Patent: August 27, 2024Assignee: SURFACE OPHTHALMICS, INC.Inventors: Kamran Hosseini, Dennis Elias Saadeh, Richard L. Lindstrom
-
Patent number: 12064442Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.Type: GrantFiled: June 17, 2022Date of Patent: August 20, 2024Assignee: GLENMARK SPECIALTY S.A.Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram M. Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
-
Patent number: 12042500Abstract: The present disclosure relates to ocular mucoadhesive pharmaceutical compositions comprising fluoroquinolone antibiotic, chitosan, polyvinyl alcohol and polyvinylpyrrolidone, their uses and methods of using such compositions.Type: GrantFiled: April 3, 2019Date of Patent: July 23, 2024Assignees: HYDERABAD EYE RESEARCH FOUNDATION, BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE (BITS) PILANIInventors: Sudeep Kumar Gade, Prashant Garg, Venkata Vamsi Krishna Venuganti
-
Patent number: 12025623Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.Type: GrantFiled: December 16, 2019Date of Patent: July 2, 2024Assignee: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Patent number: 11844781Abstract: The polymeric clotrimazole biofilm for the treatment of otomycosis contains clotrimazole or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient in a polymer biofilm thug delivery vehicle. The polymer may be a bio compatible polymer, such as hydroxypropylmethylcellulose (HPMC). Propylene glycol may be added to the mixture as a plasticizer to promote formation of the film. The drug and the polymer may be solvated in a casting solvent and then mixed in a 1:3 ratio of drug:polymer. About 15% propylene glycol may be added to the mixture, which is then heated at 40° C. until a thin, flexible film forms. A round, knife-thick patch of the biofilm may be applied to the patient's ear through the external canal and over the tympanic membrane.Type: GrantFiled: July 12, 2023Date of Patent: December 19, 2023Assignee: KING FAISAL UNIVERSITYInventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Ahmed Mohammed Abu-Dief Mohammed, Amr Embaby Elsayed Karamany, Mahmoud Ibrahim Mahmoud Abdelmagid, Mohammed Sherif Saddik Ibrahim, Ali Khames Abd Eltwab Morsy
-
Patent number: 11833152Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).Type: GrantFiled: July 19, 2021Date of Patent: December 5, 2023Assignee: Incyte CorporationInventors: Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
-
Patent number: 11833134Abstract: The polymeric clotrimazole biofilm for the treatment of otomycosis contains clotrimazole or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient in a polymer biofilm drug delivery vehicle. The polymer may be a biocompatible polymer, such as hydroxypropylmethylcellulose (HPMC). Propylene glycol may be added to the mixture as a plasticizer to promote formation of the film. The drug and the polymer may be solvated in a casting solvent and then mixed in a 1:3 ratio of drug:polymer. About 15% propylene glycol may be added to the mixture, which is then heated at 40° C. until a thin, flexible film forms. A round, knife-thick patch of the biofilm may be applied to the patient's ear through the external canal and over the tympanic membrane.Type: GrantFiled: February 6, 2023Date of Patent: December 5, 2023Assignee: KING FAISAL UNIVERSITYInventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Ahmed Mohammed Abu-Dief Mohammed, Amr Embaby Elsayed Karamany, Mahmoud Ibrahim Mahmoud Abdelmagid, Mohammed Sherif Saddik Ibrahim, Ali Khames Abd Eltwab Morsy
-
Patent number: 11752141Abstract: The present invention describes the use of a NK1-antagonist, in constant combination with pyridostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective pyridostigmine bromide daily dose without the dose-limiting gastro-intestinal adverse effects.Type: GrantFiled: January 24, 2020Date of Patent: September 12, 2023Assignee: DAS-MG, Inc.Inventor: Kathleen Clarence-Smith
-
Patent number: 11723911Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: GrantFiled: January 25, 2021Date of Patent: August 15, 2023Assignee: M ET P PHARMA AGInventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
-
Patent number: 11717499Abstract: The subject invention is directed to the treatment of inflammatory disorders by administration of N,N-dimethylacetamide and its mono-methylated metabolites. The compounds are useful in the management or treatment of inflammatory disorders, such as generative inflammation associated preterm labor and premature rupture of membranes leading to preterm birth.Type: GrantFiled: June 28, 2012Date of Patent: August 8, 2023Inventors: Sandra Eve Reznik, Charles R. Ashby, Jr., Jerome Owen Cantor
-
Patent number: 11707467Abstract: Described here are substantially pure (17-?)-3-Oxoandrost-4-en-17-yl tridecanoate compositions, methods of their preparation and uses thereof.Type: GrantFiled: March 27, 2019Date of Patent: July 25, 2023Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivasan Venkateshwaran, Joel Frank, Amy Jo Portlock
-
Patent number: 11663529Abstract: A system and method for automatically calculating an accurate recommended dosage for hormone replacement therapy and automating the life cycle of a patient's treatment over time. The system and method can automatically acquire relevant patient parameters and apply a consistent formulaic approach to help reduce incorrect dosage determinations. A pellet insertion size may be determined and documented based on a calculated dosage, and an insertion side and lot numbers may be tracked and managed. In addition, corresponding revenues may be tracked and profitability may be reported for hormone replacement therapy practices.Type: GrantFiled: May 3, 2022Date of Patent: May 30, 2023Assignee: The SottoPelle Group, LLCInventor: Gino Tutera
-
Patent number: 11642293Abstract: A composition comprising at least two visually distinguishable phases, comprises at least one fatty phase with oil, at least one aqueous phase with hydrophilic gelling agent, and at least one compound chosen from N,N-dimethylglycine derivatives, alkyl(poly)glucosides, or a mixture thereof.Type: GrantFiled: October 25, 2017Date of Patent: May 9, 2023Assignee: L'OREALInventors: Xiaoying Hu, Runshuang Lu, Lingling Sun, Xiuxia Wang
-
Patent number: 11564902Abstract: An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration.Type: GrantFiled: September 16, 2020Date of Patent: January 31, 2023Assignee: Ventis PharmaInventors: Jeremy Poulsen, Louis Stanfield, Lawrence Volz
-
Patent number: 11497746Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.Type: GrantFiled: November 21, 2017Date of Patent: November 15, 2022Assignee: ACETYLON PHARMACEUTICALS, INC.Inventors: Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
-
Patent number: 11478417Abstract: An anhydrous and alcohol-free slow fragrance diffusive composition (lotion, gel or cream) with longer lasting properties than hydroalcoholic formula fragrance product that contains 50 to 75 percent by weight dimethicone crosspolymer gel, 0.01 to 30 percent by weight fragrance oil and 5 to 40 percent by weight volatile linear silicone fluid. Emollients may be added to moisturize the skin, improve the fragrance rendition and/or increase the miscibility of the fragrance oil in the composition when a high level of dimethicone is used (in case of a lotion for example). Moreover, a preservative and some pigments can be added to the formula to preserve the fragrant product from bacteria contamination and to improve the aesthetics respectively.Type: GrantFiled: April 3, 2020Date of Patent: October 25, 2022Assignee: AKI, Inc.Inventors: Mickael Devassine, Hrazhyna Devassine
-
Patent number: 11478530Abstract: The methods and assays described herein relate to the diagnosis, prognosis, and treatment of subjects with emphysema, COPD, and/or cigarette-induced lung damage. In some embodiments, the methods and assays relate to subjects with a decreased level of NLRX1 expression. In some embodiments, the methods and assays relate to the administration of an agonist of NLRX1 and/or an inhibitor of MAVS.Type: GrantFiled: August 9, 2018Date of Patent: October 25, 2022Assignees: BROWN UNIVERSITY, YALE UNIVERSITYInventors: Jack A. Elias, Chun Geun Lee, Min-Jong Kang
-
Patent number: 11478485Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.Type: GrantFiled: May 10, 2022Date of Patent: October 25, 2022Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
-
Patent number: 11452732Abstract: This application is directed to a homogeneous solution of an aqueous, topical composition useful for the treatment of infection and/or for the treatment of inflammation due to trauma to tissue. Specifically, this application relates to a homogeneous, aqueous composition of a quinolone antibiotic and an anti-inflammatory agent.Type: GrantFiled: September 11, 2020Date of Patent: September 27, 2022Inventor: Randal Davis
-
Patent number: 11447565Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: GrantFiled: September 11, 2017Date of Patent: September 20, 2022Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
-
Patent number: 11433082Abstract: An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating disease, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided.Type: GrantFiled: November 1, 2019Date of Patent: September 6, 2022Assignee: CyDex Pharmaceuticals, Inc.Inventors: Naomi Esaki, James D. Pipkin
-
Patent number: 11413258Abstract: Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and RAD1901.Type: GrantFiled: September 24, 2019Date of Patent: August 16, 2022Assignee: Radius Pharmaceuticals, Inc.Inventor: Gary Hattersley
-
Patent number: 11389420Abstract: The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.Type: GrantFiled: January 24, 2020Date of Patent: July 19, 2022Assignee: DAS-MG, Inc.Inventor: Kathleen Clarence-Smith
-
Patent number: 11390654Abstract: Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.Type: GrantFiled: August 30, 2017Date of Patent: July 19, 2022Inventor: Christopher Joseph Soares
-
Patent number: 11364198Abstract: Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent.Type: GrantFiled: April 5, 2019Date of Patent: June 21, 2022Assignee: BAUSCH HEALTH IRELAND LIMITEDInventors: Arturo Angel, Chandelle Hermes
-
Patent number: 11344531Abstract: The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.Type: GrantFiled: March 27, 2015Date of Patent: May 31, 2022Assignees: Servicio Andaluz de Salud, Universidad de GranadaInventors: Darío Acuña Castroviejo, Germaine Escames Rosa, Pablo Bueno Laraño, Alfonso Mansilla Roselló, José Antonio Ferrón Orihuela, José Jorge Hernández Magdalena, Miguel Ángel Calleja Hernández, Desirée González Callejas, Ana Comino Pardo, Carmen Olmedo Martín, Carmen Venegas Maldonado
-
Patent number: 11337987Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.Type: GrantFiled: May 7, 2021Date of Patent: May 24, 2022Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
-
Patent number: 11332494Abstract: An oxysterol or oxysterol-like compound is provided, which finds use in treating and/or targeting cancer.Type: GrantFiled: April 25, 2017Date of Patent: May 17, 2022Assignee: Fernando Thome KreutzInventor: Fernando Thome Kreutz
-
Patent number: 11324772Abstract: The present invention relates to a periodontal gel composition, more particularly to a liquid composition having a low viscosity at ambient temperature, which upon warming to body temperature solidifies into a viscous gel and then releases a therapeutic agent, e.g., an antibacterial agent, in a sustained release manner; and to a method of use.Type: GrantFiled: February 27, 2018Date of Patent: May 10, 2022Assignee: PRUDENTIX LTD.Inventors: Keren Mevorat Kaplan, Dadi Segal, Danny Rosenbaum, Igal Liapis, Igor Makarovsky, Meir Stern
-
Patent number: 11324694Abstract: A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.Type: GrantFiled: October 28, 2021Date of Patent: May 10, 2022Assignee: CMPD Licensing, LLCInventor: Jay Richard Ray, II
-
Patent number: 11304960Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.Type: GrantFiled: January 8, 2009Date of Patent: April 19, 2022Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
-
Patent number: 11299497Abstract: The present invention relates to novel substituted tetrahydropyran dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).Type: GrantFiled: December 14, 2018Date of Patent: April 12, 2022Assignee: UNION therapeutics A/SInventors: Jens Larsen, Simon Feldbaek Nielsen, Peter Andersen
-
Patent number: 11292799Abstract: The present invention relates to novel substituted azetidine dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).Type: GrantFiled: December 14, 2018Date of Patent: April 5, 2022Assignee: UNION THERAPEUTICS A/SInventors: Mark Andrews, Daniel Rodriguez Greve, Jens Larsen
-
Patent number: 11266663Abstract: Described herein are neurosteroids and analogues thereof and derivatives thereof, including, but not limited to, allopregnanolone, allopregnanolone analogues, and derivatives thereof that can be used for treatment of a neuropsychiatric disorder and/or symptom thereof. Also described herein are pharmaceutical formulations containing an effective amount of a neurosteroids and analogues thereof and derivatives thereof, where the effective amount can be effective for treating a neuropsychiatric disorder and/or symptom thereof. Also described herein are methods of treating a neuropsychiatric disorder and/or a symptom thereof in a subject in need thereof.Type: GrantFiled: June 22, 2018Date of Patent: March 8, 2022Assignee: The Board of Trustees of the University of IllinoisInventors: Graziano Pinna, Andrea Locci
-
Patent number: 11268952Abstract: The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers, savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.Type: GrantFiled: January 16, 2020Date of Patent: March 8, 2022Assignee: Firmenich IncorporatedInventors: Catherine Tachdjian, Andrew P. Patron, Sara L. Adamski-Werner, Farid Bakir, Qing Chen, Vincent Darmohusodo, Stephen Terrence Hobson, Xiaodong Li, Ming Qi, Daniel H. Rogers, Marketa Rinnova, Guy Servant, Xiao-Qing Tang, Mark Zoller, David Wallace, Amy Xing, Klaus Gubernator
-
Patent number: 11260062Abstract: Provided is a composition for treating or ameliorating lung cancer including a glucocorticoid-based compound, a glucocorticoid-based compound and an mTOR inhibitor, or a glucocorticoid-based compound and an AMPK inhibitor as an active ingredient. The glucocorticoid-based compounds inhibit the growth of cancer cells by suppressing NRF2 in KEAP1 mutant lung cancer or KEAP1 and LKB1 mutant lung cancer, and exhibit a more potent anticancer effect when used in combination with the mTOR inhibitor, and thus the compounds can be effectively used as anticancer agents for mutant lung cancer. Further, the glucocorticoid-based compounds exhibit a strong anticancer synergistic effect in a low nutritional state when treated in combination with an AMPK inhibitor in KEAP1 and LKB1 normal lung cancer, and thus the compounds can also be used as an anticancer agent for KEAP1 normal lung cancer.Type: GrantFiled: November 2, 2016Date of Patent: March 1, 2022Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventor: Sang-Min Jeon
-
Patent number: 11241426Abstract: Provided is an aqueous composition for ophthalmic or nasal administration comprising levocetirizine or its salt. In one embodiment, the composition comprises levocetirizine or its salt at a levocetirizine concentration of 0.05-0.5% (w/v). The composition may further comprise a surface active agent and/or an organic acid salt.Type: GrantFiled: February 9, 2018Date of Patent: February 8, 2022Assignee: Nitto Medic Co., Ltd.Inventor: Mineo Onuki
-
Patent number: 11229655Abstract: The invention provides a fulvestrant composition comprising a pharmaceutically acceptable vehicle and not more than 2% total impurities and which, optionally, is free of a non-aqueous ester solvent. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject.Type: GrantFiled: January 23, 2019Date of Patent: January 25, 2022Assignee: Fresenius Kabi USA, LLCInventor: Jabar A. Faraj
-
Patent number: 11224575Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.Type: GrantFiled: March 19, 2019Date of Patent: January 18, 2022Assignee: Aragon Pharmaceuticals, Inc.Inventor: Geert Verreck
-
Patent number: 11197822Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: GrantFiled: March 11, 2019Date of Patent: December 14, 2021Assignees: The Regents of the University of California, Meritage Pharma, Inc.Inventors: Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
-
Patent number: 11180488Abstract: The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; L is C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 is hydrogen, C1-6 alkyl, C1-6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; R4 is C1-10 alkyl, C1-10 deuterated alkyl, C1-10 haloalkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(C1-6 alkylene)-(C3-8 cyclType: GrantFiled: December 18, 2018Date of Patent: November 23, 2021Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Hao Zhang, Yan Shi, Jun Li
-
Patent number: 11166978Abstract: The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.Type: GrantFiled: July 30, 2020Date of Patent: November 9, 2021Assignee: Seanergy Dermatology Ltd.Inventor: Doron Friedman
-
Patent number: 11154528Abstract: An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration.Type: GrantFiled: October 1, 2018Date of Patent: October 26, 2021Assignee: Ventis PharmaInventors: Jeremy Poulsen, Louis Stanfield, Lawrence Volz
-
Patent number: 11154527Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.Type: GrantFiled: August 26, 2019Date of Patent: October 26, 2021Assignee: The Children's Mercy HospitalInventors: Susan Abdel-Rahman, Barry L. Preuett, J. Steven Leeder
-
Patent number: 11123323Abstract: The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).Type: GrantFiled: July 15, 2016Date of Patent: September 21, 2021Assignee: MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT MBHInventor: Harald Greve